Vaishali Pharma Ltd.

CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : sales@vaishalipharma.com
Website : www.vaishalipharma.com
CIN - L52310MH2008PLC181632

Date: 04th September, 2026

To,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.
Stock Code: VAISHALI

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Company has received the Listing Approval from the National Stock Exchange of India Limited ("NSE") vide its letter bearing Reference No. NSE/LIST/56477 dated 03rd September, 2026.

NSE has approved the listing and admission to dealings of 45,37,865 (Forty-Five Lakhs Thirty-Seven Thousand Eight Hundred Sixty-Five) Equity Shares of face value of Rs. 2/- each, allotted on a preferential basis, bearing distinctive numbers from 130462131 to 134999995, subject to receipt of confirmation from the depositories, namely National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), regarding credit of the said equity shares to the beneficiaries' accounts.

A copy of the Listing Approval Letter received from NSE is enclosed herewith for the information of the Exchange.

Kindly take the above information on record.

Thanking You,

Yours Faithfully,

For Vaishali Pharma Limited

Vishwa Bipinbhai Mekhia

Digitally signed by Vishwa Bipinbhai Mekhia
DN: c=IN, o=Personal, postalCode=400064, st=Maharashtra, serialNumber=fa5040b8201cbfc67b123d0d6135eee19949b54168b2156228e4f1a496f012e8, cn=Vishwa Bipinbhai Mekhia
Date: 2026.09.04 15:09:27 +05'30'

Vishwa Mekhia
Company Secretary and Compliance Officer

Ref: NSE/LIST/56477 September 03, 2026

The Company Secretary
Vaishali Pharma Limited

Dear Sir/Madam,

Sub: In - Principle approval for listing of 45,37,865 Equity shares of Rs. 2/- each allotted on preferential basis.

We are in receipt of your application for in-principle approval for listing of 45,37,865 Equity shares of Rs. 2/- each allotted on preferential basis bearing distinctive numbers from 130462131 to 134999995.

We have perused the listing application and the related documents/details submitted by you for listing of the above shares.

We are pleased to grant the in-principle approval for listing of the above shares on the Exchange. The said shares would be listed and admitted to dealings on the Exchange on receipt of the confirmation from the depositories i.e. NSDL/CDSL for credit of beneficiaries' accounts.

The Exchange reserves its right to withdraw its in-principle approval for listing at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc.

Yours faithfully,
For National Stock Exchange of India Limited

Pooja Pashte
Manager

Cc:
National Securities Depository Limited
Central Depository Services Limited

P.S. Checklist of all the further issues is available on website of the exchange at the following URL: https://www.nseindia.com/companies-listing/raising-capital-further-issues-main-sme-checklist

The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name "NEAPS APP"

This Document is Digitally Signed

Signer: POOJA RISHIKESH PASHTE
Date: Thu, Sep 3, 2026 17:52:36 IST
Location: NSE